SparingVision Announces Poster Presentations at two upcoming conferences: ARVO 2024 Annual Meeting and ASGCT 27th Annual Meeting
Paris, 11 April 2024 – SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the treatment of retinal disease, today announces that it will present two posters at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting to be held from 5-9 May, and one poster at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place on May 7-11.
Details of the three presentations can be found below:
Poster presentations at ARVO, Seattle, Washington, USA.
Poster Presentation: PRODYGY: A First-in-Human Trial of Rod-Derived Cone Viability Factor (RdCVF) Gene Therapy in Subjects with Rod-Cone Dystrophy
Date and Time: 7 May, 8:30 AM -10:15 AM PDT, Poster 3091 – A0355
Presenter: Joseph N. Martel, MD, University of Pittsburgh School of Medicine
Session Title: Retinitis pigmentosa and macular diseases
Session Number: 320
Poster Presentation: Evolution of Markers of Retinal Degeneration After One Year of Prospective Follow-up in Patients with Rod-Cone Dystrophy: The Natural History Study PHENOROD2
Date and Time: 7 May, 8:30 AM -10:15 AM PDT, Poster 3090 – A0354
Presenter: Laure Blouin
Session Title: Retinitis pigmentosa and macular diseases
Session Number: 320
Poster presentation at ASGCT, Baltimore, Maryland, USA.
Title: PRODYGY: A First-in-Human Trial of Rod-Derived Cone Viability Factor (RdCVF) Gene Therapy in Subjects with Rod-Cone Dystrophy
Date and Time: 8 May, 12:00 PM – 7:00 PM EDT
Presenter: James Gow, MD, MBA, MS
Session Title: Wednesday Posters: Gene Therapy Trials – In Vivo Modification
Abstract #: 916
**ENDS**